Original results did not show a significant improvement in survival with capecitabine across all TNBC cases, but a pre-planned analysis of an IHC-defined stratum for the basal-like subtype of TNBC showed that although those expressing the basal biomarkers cytokeratin 5/6 (CK5/6) or EGFR ( 23 ) did not benefit from capecitabine, those classified as non-basal by IHC did have a highly significant benefit from capecitabine with an OS hazard ratio (HR) of 0.43 versus 1.23 ( P interaction = 0.005) and a pronounced trend toward a better DFS with an HR of 0.53 versus 0.94 ( P interaction = 0.06) for IHC non-basal versus basal ( 21 ).
← all excerpts
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
1
—
—